Argenica Therapeutics (ASX:AGN) clears a major regulatory hurdle with positive drug-drug interaction results for ARG-007, bringing the company closer to advancing its neuroprotective therapy for stroke.
Brookside Energy has unveiled its Riverbend Area of Interest in the Anadarko Basin, a 24 square mile position with the potential to materially grow reserves and deliver strong well economics.
Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007 delivers lasting protection where no approved therapy exists.
Orthocell’s FDA clearance for its Remplir™ nerve repair device marks a major commercial milestone, unlocking access to the US$1.6 billion US market and positioning the Perth-based company for global growth and profitability.